Benzodiazepines
Key Points
- Benzodiazepines enhance GABA-A receptor activity → CNS depression → anxiolysis, sedation, anticonvulsant, and muscle relaxant effects.
- Schedule IV controlled substances due to tolerance, physical dependence, and abuse potential — use short-term only for anxiety.
- Respiratory depression is the most serious adverse effect; antidote is flumazenil.
- Children and older adults are more susceptible to sedation/respiratory depression and paradoxical reactions.
- Continued use can lead to misuse, substance use disorder, addiction, and clinically significant physical dependence.
- Abrupt discontinuation or rapid dose reduction after prolonged use can cause life-threatening withdrawal reactions, including seizures.
Pathophysiology
Benzodiazepines act as positive allosteric modulators of the GABA-A receptor, enhancing chloride ion influx and hyperpolarizing neurons. This increases the frequency of chloride channel opening (not duration — that is barbiturates). The result is CNS depression affecting the limbic system (anxiety), cortex (seizures), and spinal cord (muscle spasm).
Tolerance develops to sedative effects; physical dependence develops within weeks of daily use. Withdrawal is characterized by rebound anxiety, tremor, diaphoresis, and, in severe cases, seizures.
Classification by Duration
| Duration | Examples | Clinical Use |
|---|---|---|
| Short-acting | Triazolam, midazolam (Versed), oxazepam | Procedural sedation, acute anxiety; less hangover |
| Intermediate-acting | Lorazepam (Ativan), alprazolam (Xanax), temazepam | Anxiety, alcohol withdrawal, acute seizures |
| Long-acting | Diazepam (Valium), chlordiazepoxide (Librium), clonazepam (Klonopin) | Alcohol withdrawal protocol, seizure disorders |
Nursing Assessment
NCLEX Focus
Assess respiratory rate and sedation level before and after administration; have flumazenil and respiratory support available for IV benzodiazepines.
- Assess baseline respiratory rate, oxygen saturation, and level of consciousness before administration.
- Assess for concurrent CNS depressant use: opioids, alcohol, antihistamines — additive respiratory depression.
- Assess pregnancy status: benzodiazepines are contraindicated in pregnancy (neonatal withdrawal syndrome, teratogenicity).
- Screen for high-risk contraindications: acute narrow-angle glaucoma, severe respiratory insufficiency/sleep apnea, severe hepatic insufficiency, and myasthenia gravis.
- Use added caution in renal impairment because active metabolites may accumulate and increase oversedation/respiratory-depression risk.
- Assess fall risk in older adults — Beers Criteria lists benzodiazepines as potentially inappropriate due to cognitive impairment and fall risk.
- Monitor for paradoxical reactions in children and older adults (agitation, tremor, hallucinations, or disinhibition).
- In suspected withdrawal, assess for escalating severity cues (hallucinations, severe agitation, psychosis, tachycardia/hypertension, hyperthermia, diaphoresis, and seizure risk), especially after abrupt cessation.
Nursing Interventions
- Administer IV benzodiazepines slowly; have flumazenil (benzodiazepine reversal agent), oxygen, and suction at bedside.
- Flumazenil dosing: 0.2 mg IV over 15 seconds; may repeat at 1-minute intervals; duration shorter than benzodiazepine — watch for re-sedation and seizure risk (especially in chronic users).
- Teach patients not to stop benzodiazepines abruptly after prolonged use — taper under medical supervision.
- For withdrawal treatment plans, anticipate conversion to a longer-acting benzodiazepine and gradual tapering (commonly about 10-25% dose reduction every 1-2 weeks) based on symptoms and safety.
- Delay driving or hazardous tasks for 24–48 hours after dosing or until drowsiness resolves.
- Avoid alcohol for at least 24–48 hours after lorazepam due to additive CNS depression.
- Caution against concurrent opioid use and assist hospitalized clients with ambulation due to fall risk.
- Reconcile interaction burden with calcium channel blockers, cimetidine, and disulfiram because these can increase benzodiazepine exposure and toxicity.
Respiratory Depression
Concurrent use of benzodiazepines and opioids carries a Black Box Warning due to the risk of profound CNS/respiratory depression, coma, and death. Monitor closely when co-prescribed.
Midazolam IV Safety
Intravenous midazolam can cause marked respiratory depression and hypoxia; continuous airway/ventilation monitoring and immediate resuscitation support are required during procedural use.
Withdrawal Seizures
Abrupt discontinuation of benzodiazepines after prolonged use causes hyperexcitable CNS state and can trigger life-threatening seizures, often within about 1-5 days of rapid cessation in high-dose/long-term users. Always taper doses when discontinuing. Long-acting agents (diazepam) are commonly used for structured taper protocols.
Pharmacology
| Drug | Route | Key Clinical Uses |
|---|---|---|
| Lorazepam (Ativan) | IV, IM, PO | Status epilepticus (first-line), acute anxiety, alcohol withdrawal |
| Diazepam (Valium) | PO, IV | Alcohol withdrawal, muscle spasm, seizure disorders |
| Midazolam (Versed) | IV, IM, intranasal | Procedural sedation, anesthesia induction |
| Alprazolam (Xanax) | PO | Panic disorder, anxiety — short-term use |
| Clonazepam (Klonopin) | PO | Seizure disorders, panic disorder |
In alcohol-withdrawal pathways, long-acting agents (for example chlordiazepoxide) can reduce abrupt symptom rebound but require oversedation monitoring when hepatic clearance is impaired or relapse with alcohol/CNS depressants occurs.
Clinical Judgment Application
Clinical Scenario
A patient with alcohol use disorder is admitted for medically managed withdrawal. Lorazepam PRN CIWA-Ar protocol is ordered.
- Recognize Cues: Alcohol withdrawal risk — benzodiazepine taper protocol initiated.
- Analyze Cues: CIWA-Ar score drives dosing frequency; goal is preventing withdrawal seizures.
- Prioritize Hypotheses: Prevention of life-threatening withdrawal seizures is the immediate priority.
- Generate Solutions: Administer per CIWA-Ar protocol; monitor closely in first 24–72 hours.
- Take Action: Administer lorazepam per protocol; monitor respiratory status and sedation level.
- Evaluate Outcomes: CIWA-Ar score decreases; no seizure activity; patient comfortable.
Related Concepts
- anxiolytics - Overlapping drug class including SSRIs, buspirone, and benzodiazepines.
- sedative-hypnotics - Drug class overview including nonbenzodiazepine Z-drugs.
- alcohol-use-disorder - Primary clinical use for withdrawal management.
- antidepressants - Often initiated with benzodiazepines for anxiety until SSRI reaches therapeutic level.
- common-neurological-disorders-recognition-and-priority-care - Lorazepam is first-line IV treatment for status epilepticus.
Self-Check
- What is the mechanism of action of benzodiazepines, and how does it differ from barbiturates?
- What is flumazenil, and when would a nurse administer it?
- Why is abrupt discontinuation of long-term benzodiazepine use dangerous?